KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 166 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Impairment of health-related quality of life for children with acute lymphoblastic leukemia over the first year of therapy: A report from the DFCI ALL Consortium. PMID 37461125 · Pediatr Blood Cancer · 2023-Nov 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L B
旧查询独有 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non-Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy. PMID 37196430 · J Clin Oncol · 2023-May-20 The record describes a randomized, drug-intervention trial in human oncology with primary time-to-event efficacy endpoints (OS, TTP). The phase is not explicitly stated in the provided metadata but is inferred as Phase III based on the trial design (randomized, control arm, survival endpoint, multi-center study type) and is consistent with the criteria for 'phase3_or_definitive'. All other required criteria are explicitly established in the abstract.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up. PMID 36972491 · J Clin Oncol · 2023-May-20 The record describes a phase III randomized trial with drug intervention and primary/key secondary time-to-event efficacy endpoints (PFS and OS). The abstract provides updated results from the original trial, fulfilling the criteria for an eligible record. The deterministic review flagged unclear randomization evidence, but the abstract explicitly states it is a 'phase III adaptive trial' comparing two arms, confirming randomization.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 1 Figure · 6 Panel · risk visible
FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer. PMID 36469000 · Clin Cancer Res · 2023-May-01 Meets all criteria: oncology, human, randomized, definitive trial phase (VISION), drug intervention, primary time-to-event efficacy endpoint (OS with HR), and original result report. No exclusions apply.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 1 Figure · 1 Panel · risk visible
COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF. PMID 37309702 · Future Oncol · 2023-May Abstract explicitly reports a randomized Phase III oncology trial with drug interventions and a time-to-event efficacy endpoint (progression-free survival, PFS), meeting all inclusion criteria for a 5-year updated result.
H L B
旧查询独有 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials. PMID 36521078 · J Clin Oncol · 2023-Mar-01 The record is from a long-term follow-up of two definitive Phase III randomized trials (TEXT and SOFT) in premenopausal breast cancer. It reports drug interventions (exemestane + OFS vs tamoxifen + OFS) with primary/key secondary time-to-event efficacy endpoints (DFS, DRFI, OS) including hazard ratios and p-values. It is an original formal result report.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 1 Figure · 4 Panel · risk visible
Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT. PMID 36493334 · J Clin Oncol · 2023-Mar-01 The record is a long-term follow-up report from a phase III randomized controlled trial (SOFT) evaluating adjuvant endocrine therapy in human breast cancer, with drug intervention and primary/key secondary time-to-event endpoints (DFS, OS). All required criteria are explicitly established.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs' development. PMID 36759721 · Br J Cancer · 2023-Mar 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H L B
旧查询独有 eligibleexplicit_phase3_randomized confirmed 3 Figure · 5 Panel · risk visible
Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up. PMID 36494006 · Ann Oncol · 2023-Mar The abstract explicitly details results from two large randomized trials (KEYNOTE-045 and KEYNOTE-052) evaluating pembrolizumab in metastatic urothelial carcinoma. KEYNOTE-045 is a randomized, Phase III trial with primary time-to-event endpoints (OS, PFS), meeting all eligibility criteria. KEYNOTE-052 is a single-arm trial, but the overall report's inclusion is justified by the definitive Phase III data from KEYNOTE-045.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Vincristine and dexamethasone pulses in addition to maintenance therapy among pediatric acute lymphoblastic leukemia (GD-ALL-2008): An open-label, multicentre, randomized, phase III clinical trial. PMID 36877527 · Am J Hematol · 2023-Jun 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L B
旧查询独有 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Preoperative Treatment of Locally Advanced Rectal Cancer. PMID 37272534 · N Engl J Med · 2023-Jul-27 命中用户提供的消化道肿瘤阳性参考集。
B
影子组漏检补回 eligiblepositive_reference confirmed 1 Figure · 3 Panel · risk visible
Author Correction: Phase III study of HR-positive/HER2-negative/lymph node-positive breast cancer non-responsive to primary chemotherapy: a randomized trial. PMID 37488099 · NPJ Breast Cancer · 2023-Jul-24 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H B
影子组漏检补回 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227. PMID 36223558 · J Clin Oncol · 2023-Feb-20 The record describes a Phase III randomized trial (CheckMate 227) with a drug-containing intervention (nivolumab plus ipilimumab vs. chemotherapy) and a primary time-to-event efficacy endpoint (5-year overall survival). The abstract confirms the randomized design, human participants, oncology focus, and original result reporting. The phase is inferred from the trial name (CheckMate 227 is known as a Phase III trial), and the abstract's methods and results support definitive Phase III evidence. The report type is primary, as it presents 5-year survival outcomes from the trial.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 3 Figure · 16 Panel · risk visible
Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial. PMID 36400384 · Ann Oncol · 2023-Feb 命中用户提供的消化道肿瘤阳性参考集。
B
影子组漏检补回 eligiblepositive_reference needs_review 0 Figure · 0 Panel · risk not_assessed
Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized Trial. PMID 38100992 · J Clin Oncol · 2023-Dec-20 The record describes a randomized, drug-controlled trial with primary efficacy endpoints including survival (a time-to-event measure). The publication type ('Clinical Trial') and the description as a 'definitive trial' provide sufficient evidence for Phase III/definitive status. All required criteria are explicitly met in the abstract.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649. PMID 37713657 · J Clin Oncol · 2023-Dec-10 命中用户提供的消化道肿瘤阳性参考集。
B
影子组漏检补回 eligiblepositive_reference confirmed 1 Figure · 4 Panel · risk visible
Long-term outcome of children with acute promyelocytic leukemia: a randomized study of oral versus intravenous arsenic by SCCLG-APL group. PMID 38052803 · Blood Cancer J · 2023-Dec-05 The record meets all core eligibility criteria: it is an original report of a randomized trial in a human oncology setting (pediatric APL) with a drug-containing intervention (ATO vs. RIF) and a primary time-to-event efficacy endpoint (5-year EFS). While the explicit phase is not stated in the provided metadata, the trial design (multicenter, randomized, non-inferiority, with a definitive efficacy endpoint) is consistent with a Phase III or equivalent definitive trial. Therefore, it is eligible.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 1 Figure · 4 Panel · risk visible
First-line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non-squamous non-small cell lung cancer: Updated survival analysis of the ONO-4538-52/TASUKI-52 randomized controlled trial. PMID 37641544 · Cancer Med · 2023-Aug Record meets all eligibility criteria: it is an original report of a human oncology Phase III randomized controlled trial with a drug-containing intervention and a primary time-to-event efficacy endpoint (overall survival).
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 2 Figure · 4 Panel · risk visible
[First-line maintenance therapy of adult patients with BCG-naïve high-risk non-muscle-invasive bladder cancer - A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants with BCG-naïve High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) - SunRISe-3 - AB 85/23 of AUO]. PMID 37541235 · Aktuelle Urol · 2023-Aug 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L B
旧查询独有 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial. PMID 37211045 · Ann Oncol · 2023-Aug The record describes the final OS results of the PAOLA-1/ENGOT-ov25 trial, a randomized, placebo-controlled Phase III trial of olaparib plus bevacizumab vs bevacizumab alone in advanced ovarian cancer. It includes a drug-containing intervention, reports key time-to-event efficacy endpoints (OS, PFS), and is an original formal result report. The deterministic review's phase3 evidence concern is resolved by the trial identifier (ENGOT-ov25) and context, which are standard for Phase III oncology trials.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651. PMID 36473143 · J Clin Oncol · 2023-Apr-20 Explicitly meets all criteria: Phase III randomized trial in human oncology with drug intervention, final results reporting OS and PFS (time-to-event endpoints), and original formal-result report.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 3 Figure · 8 Panel · risk visible
Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final Analysis. PMID 36716289 · Clin Cancer Res · 2023-Apr-14 The record is eligible: it is an original final result report from a randomized Phase III trial (PERTAIN) evaluating drug interventions (pertuzumab, trastuzumab, AI) with a primary time-to-event efficacy endpoint (PFS) and key secondary endpoint (OS) in human oncology (breast cancer).
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 2 Figure · 8 Panel · risk visible
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. PMID 36989610 · J Clin Oncol · 2023-Apr-01 The record describes a definitive, randomized, Phase III-style clinical trial in human breast cancer (operable, stages I/II) comparing preoperative vs. postoperative AC chemotherapy. It reports primary time-to-event efficacy results (DFS, DDFS, survival) with p-values and includes tumor response as a prognostic factor. No major exclusion criteria apply.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer. PMID 38319800 · NEJM Evid · 2022-Sep The record explicitly meets all required eligibility criteria for inclusion in the cohort.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Adjuvant Capecitabine Following Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomized Clinical Trial. PMID 36227615 · JAMA Oncol · 2022-Oct-13 The record meets all eligibility criteria: it is an original result report of a randomized oncology trial in humans with a drug intervention (capecitabine) and a primary time-to-event efficacy endpoint (failure-free survival, reported with Kaplan-Meier data and hazard ratio). While the explicit phase (III/IIIb or II/III) is not labeled in the provided metadata, the trial design (open-label RCT, large sample size, definitive comparison of adjuvant therapy vs. observation in locally advanced disease, with 3+ years follow-up and primary efficacy endpoint) is consistent with a Phase III-level definitive trial in oncology. The deterministic review flagged phase evidence as unclear, but the contextual evidence strongly supports phase3_or_definitive as true.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 1 Figure · 4 Panel · risk visible
FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer. PMID 35679021 · Clin Cancer Res · 2022-Oct-03 The record describes an original FDA approval summary of the COSMIC-311 trial, which is a randomized, double-blind, placebo-controlled Phase III study evaluating cabozantinib in differentiated thyroid cancer. The primary efficacy endpoint is PFS, a time-to-event endpoint, with explicit Kaplan-Meier median estimates and hazard ratio reported. All eligibility criteria are explicitly established in the abstract.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial. PMID 36048457 · JAMA Oncol · 2022-Oct-01 The record describes a randomized, placebo-controlled, double-blind Phase III clinical trial (CANTATA) with a drug-containing intervention (telaglenastat plus cabozantinib) and a primary time-to-event efficacy endpoint (progression-free survival) with hazard ratio and confidence interval reported. All required criteria are explicitly established.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. PMID 34954044 · Ann Oncol · 2022-Mar The record describes a randomized Phase III trial (HER2CLIMB) evaluating a drug-containing intervention (tucatinib) for a human malignant neoplasm (HER2+ metastatic breast cancer) with primary/key secondary time-to-event efficacy endpoints (OS and PFS). The report is the final overall survival analysis, providing original formal results.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma. PMID 35657079 · N Engl J Med · 2022-Jun-30 The record explicitly describes a Phase III randomized trial (SHINE, NCT01776840) of ibrutinib combination therapy in untreated mantle-cell lymphoma with a primary time-to-event endpoint (PFS) and HR reported. All required eligibility criteria are met.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial. PMID 35254888 · J Clin Oncol · 2022-Jun-20 The record describes a Phase III randomized controlled trial in human oncology (muscle-invasive bladder cancer) comparing two drug-containing chemotherapy regimens (dd-MVAC vs. GC) with a primary time-to-event efficacy endpoint (progression-free survival at 3 years). The abstract reports formal results including hazard ratios and p-values for PFS and secondary endpoints (time to progression, overall survival). It is an original primary result report, not a subgroup, safety, or economic analysis.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma. PMID 35830649 · N Engl J Med · 2022-Jul-28 The record is an eligible original formal result report of a Phase III randomized trial in human oncology, with a drug-containing intervention and a primary/key secondary time-to-event efficacy endpoint (OS, PFS).
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
FDA Approval Summary: Oral Azacitidine for Continued Treatment of Adults with Acute Myeloid Leukemia Unable to Complete Intensive Curative Therapy. PMID 35325108 · Clin Cancer Res · 2022-Jul-15 Eligible based on explicit criteria: oncology, human, randomized Phase III trial (QUAZAR AML-001), drug intervention, original primary result with OS time-to-event endpoint.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 1 Figure · 1 Panel · risk visible
Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. PMID 35427411 · Blood · 2022-Jul-14 The record describes a randomized Phase III trial (E1912) in human CLL with drug-containing interventions (IR vs. FCR) and reports primary (PFS) and key secondary (OS) time-to-event efficacy endpoints with HRs. The updated results constitute original formal long-term results of the trial.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 5 Figure · 15 Panel · risk visible
FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation. PMID 35259259 · Clin Cancer Res · 2022-Jul-01 The record describes a double-blind, placebo-controlled, randomized trial (Study AG120-C-005) with a drug intervention (ivosidenib vs. placebo). It has a primary time-to-event efficacy endpoint (PFS, with HR) and a key secondary time-to-event endpoint (OS, with HR). The publication type includes 'Randomized Controlled Trial', and the text confirms a phase 3/definitive trial context (pivotal trial for FDA approval). All required criteria are met.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 2 Figure · 2 Panel · risk visible
Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. PMID 35562406 · Leukemia · 2022-Jul The record describes the 7-year results of the IELSG32 randomized trial, which is a definitive Phase III trial (implied by the multi-arm randomized design and the context of a 'randomized trial' with comparative efficacy endpoints). It reports long-term overall survival (OS), a key time-to-event endpoint, for drug-containing interventions (MATRix vs. other arms) in a human oncology setting. The publication is the primary result report of the trial, not a subgroup, secondary, safety, or economic analysis.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer. PMID 35075138 · Sci Rep · 2022-Jan-24 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L B
旧查询独有 eligiblephase3_publication_type confirmed 1 Figure · 4 Panel · risk visible
Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial. PMID 34895479 · Lancet Oncol · 2022-Jan The trial is a large, randomized, open-label, multinational study in children/adolescents with Hodgkin lymphoma, comparing chemotherapy regimens (COPP vs COPDAC) and investigating radiotherapy omission. It reports primary efficacy results (event-free survival at 5 years) with Kaplan-Meier estimates and meets criteria for a definitive Phase III randomized trial with drug intervention and time-to-event endpoint.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 1 Figure · 2 Panel · risk visible
Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial. PMID 34468869 · Gastric Cancer · 2022-Jan 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L B
旧查询独有 eligiblephase3_publication_type confirmed 3 Figure · 8 Panel · risk visible
Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma. PMID 34304248 · Leukemia · 2022-Jan 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L B
旧查询独有 eligiblephase3_publication_type needs_review 1 Figure · 2 Panel · risk unclear
Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03). PMID 34995105 · J Clin Oncol · 2022-Feb-10 The record describes the primary efficacy results of the PALLAS trial, which is a large, randomized Phase III adjuvant study in early breast cancer comparing palbociclib+ET vs. ET alone. The primary endpoint is invasive disease-free survival (a time-to-event outcome). All required criteria are explicitly established in the provided text.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Comparison of 3 Paclitaxel-Based Chemoradiotherapy Regimens for Patients With Locally Advanced Esophageal Squamous Cell Cancer: A Randomized Clinical Trial. PMID 35188552 · JAMA Netw Open · 2022-Feb-01 The record explicitly describes a randomized clinical trial in human oncology patients with a drug-containing intervention, reporting primary (OS) and secondary (PFS) time-to-event efficacy endpoints with hazard ratios. The phase is not explicitly labeled in the abstract, but the trial design (definitive chemoradiotherapy comparing standard regimens) and presentation of definitive results with mature follow-up (median 46 months) strongly indicate it is a definitive Phase III trial, consistent with the 'phase3_or_definitive' criterion for eligibility.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 1 Figure · 2 Panel · risk visible
First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients. PMID 35158207 · ESMO Open · 2022-Feb The record reports results from the CheckMate 227 trial, which is a definitive Phase III randomized controlled trial in human oncology. It includes a drug-containing intervention and reports key time-to-event efficacy endpoints (OS, PFS) for a pre-specified subpopulation, making it an eligible primary result report.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 1 Figure · 2 Panel · risk visible
Prospective Randomized Controlled Trial Comparing Adjuvant Chemotherapy vs. No Chemotherapy for Patients with Carcinoma of Gallbladder Undergoing Curative Resection. PMID 34545545 · J Gastrointest Surg · 2022-Feb The record is an original, formal-result report of a randomized trial for a human malignant neoplasm (gallbladder carcinoma) evaluating a drug-containing intervention (adjuvant chemotherapy) with a primary time-to-event efficacy endpoint (DFS). The trial design (randomized, controlled, adjuvant setting) is definitive for efficacy assessment, meeting the criteria for a Phase III or equivalent definitive trial, despite the absence of an explicit 'Phase III' label in the abstract.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer. PMID 36456573 · NPJ Breast Cancer · 2022-Dec-01 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H B
影子组漏检补回 eligibleexplicit_phase3_randomized confirmed 1 Figure · 3 Panel · risk visible
Inclusion of premenopausal women in breast cancer clinical trials. PMID 36327626 · Breast · 2022-Dec 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H B
影子组漏检补回 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab. PMID 35605176 · Blood · 2022-Aug-25 The record describes the MURANO trial, a Phase III randomized study in relapsed/refractory CLL comparing venetoclax-rituximab vs bendamustine-rituximab. It reports primary and secondary time-to-event efficacy endpoints (PFS, OS) with survival analysis, making it eligible for inclusion in an oncology KM digitization cohort.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 4 Figure · 12 Panel · risk visible
FDA Approval Summary: Margetuximab plus Chemotherapy for Advanced or Metastatic HER2-Positive Breast Cancer. PMID 34916216 · Clin Cancer Res · 2022-Apr-14 The record describes a randomized, active-controlled Phase III trial (SOPHIA) with a drug intervention and a primary time-to-event efficacy endpoint (PFS) for an oncology indication. The results are original and formal.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer. PMID 35084948 · J Clin Oncol · 2022-Apr-10 The record describes the FDA approval summary of the monarchE Phase III randomized trial, which is an original formal report with a drug intervention and primary/key secondary time-to-event efficacy endpoints (IDFS and OS) presented with hazard ratios and Kaplan-Meier analysis. All required criteria are explicitly established in the abstract.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible no_km 0 Figure · 0 Panel · risk not_applicable
Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status. PMID 34995344 · Blood · 2022-Apr-07 The record describes a Phase III randomized controlled trial with a drug-containing intervention (oral azacitidine vs placebo) and primary time-to-event efficacy endpoints (OS, RFS) in oncology (AML). The abstract explicitly states the trial phase, randomization (via placebo comparator), drug intervention, and efficacy results, establishing all required criteria.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Role of maintenance paclitaxel in epithelial ovarian cancer: An affordable option for poor resources countries (a Regional Cancer Institute study). PMID 36412415 · J Cancer Res Ther · 2022 The record explicitly states a randomized controlled trial with a drug intervention (paclitaxel) in human oncology (epithelial ovarian cancer). It reports primary (PFS) and secondary (OS) time-to-event efficacy endpoints with formal results. While the publication metadata does not explicitly label the phase, the definitive nature of the study (300 patients, randomized to maintenance therapy vs. observation after initial treatment) and the reporting of long-term outcomes (5-year OS/PFS) are consistent with a Phase III trial structure, meeting the 'phase3_or_definitive' criterion.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed